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Short-term hyperoxia does not 
exert immunologic effects during 
experimental murine and human 
endotoxemia
Dorien Kiers1,2,3, Jelle Gerretsen1, Emmy Janssen1, Aaron John1, R. Groeneveld1, 
Johannes G. van der Hoeven1,3, Gert-Jan Scheffer2, Peter Pickkers1,3 & Matthijs Kox1,2,3
Oxygen therapy to maintain tissue oxygenation is one of the cornerstones of critical care. Therefore, 
hyperoxia is often encountered in critically ill patients. Epidemiologic studies have demonstrated 
that hyperoxia may affect outcome, although mechanisms are unclear. Immunologic effects 
might be involved, as hyperoxia was shown to attenuate inflammation and organ damage in 
preclinical models. However, it remains unclear whether these observations can be ascribed to 
direct immunosuppressive effects of hyperoxia or to preserved tissue oxygenation. In contrast to 
these putative anti-inflammatory effects, hyperoxia may elicit an inflammatory response and organ 
damage in itself, known as oxygen toxicity. Here, we demonstrate that, in the absence of systemic 
inflammation, short-term hyperoxia (100% O2 for 2.5 hours in mice and 3.5 hours in humans) does 
not result in increased levels of inflammatory cytokines in both mice and healthy volunteers. 
Furthermore, we show that, compared with room air, hyperoxia does not affect the systemic 
inflammatory response elicited by administration of bacterial endotoxin in mice and man. Finally, 
neutrophil phagocytosis and ROS generation are unaffected by short-term hyperoxia. Our results 
indicate that hyperoxia does not exert direct anti-inflammatory effects and temper expectations of 
using it as an immunomodulatory treatment strategy.
In critically ill patients, the treatment paradigm “treat first what kills first” emphasizes on the avoidance 
of hypoxia and liberal oxygen supply is often the first medical intervention to be initiated, frequently 
resulting in hyperoxia at ICU admission1–4. A recent meta-analysis of observational studies revealed an 
association between hyperoxia at ICU-admission and increased mortality, albeit this was mainly due to 
increased mortality in a large subgroup of patients with cardiac arrest5. On the contrary, hyperoxia might 
also exert beneficial effects, for instance as prophylactic treatment for surgical wound infections, although 
clinical trials have yielded conflicting results6. The mechanism through which hyperoxia might exert det-
rimental or beneficial effects and contributes to outcome in critically ill patients is largely unclear, but 
immunologic effects might play a role. In vitro, short-term hyperoxia was shown to attenuate cytokine 
production7, β 2-integrin expression necessary for leukocyte adhesion8, and macrophage phagocytosis 
and killing9. Furthermore, animal studies have demonstrated that hyperoxia mitigates the inflammatory 
response and organ damage after administration of zymosan10 and cecal ligation and puncture (CLP)11,12. 
However, these beneficial effects of hyperoxia in vivo were found 20-48 hours after the inflammatory 
insult10–12. As such, it remains unclear whether these were due to direct immunosuppressive effects of 
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hyperoxia, or resulted from preserved tissue oxygenation during severe hemodynamic instability, thereby 
preventing additional tissue damage and subsequent inflammation13,14.
If hyperoxia has intrinsic anti-inflammatory effects, it could be a promising treatment option in 
inflammatory conditions in the ICU, as oxygen is affordable and widely available. However, evidence 
of direct immunologic effects of hyperoxia in animals and humans in vivo is lacking. In addition, there 
are concerns of oxygen toxicity in the lungs, characterized by a pulmonary inflammatory response and 
lung injury15,16.
In the present study, we investigated the intrinsic immunologic effects of short-term hyperoxia in 
the presence and absence of systemic inflammation elicited by administration of LPS in mice and man, 
primarily reflected by circulating cytokine levels. To evaluate possible compartmentalization of immuno-
logic effects of hyperoxia, we also determined cytokine concentrations in spleen, liver, and lung homoge-
nates in mice. Furthermore, as hyperoxia has been reported to impair leukocyte functions (e.g. cytokine 
production7, phagocytosis and killing9), whole blood ex vivo cytokine production, neutrophil phagocy-
tosis, and intracellular generation of reactive oxygen species (ROS) were assessed in humans.
Results
Effects of hyperoxia during murine endotoxemia. Hyperoxia was well tolerated and did not 
increase cytokine levels in plasma or tissue homogenates in placebo-treated mice (Fig. 1). LPS admin-
istration resulted in increased cytokine levels in tissue homogenates, with the exception of IL-6 in liver, 
and IL-10 in spleen, liver, and lung homogenates. Apart from a slight, but statistically significant, reduc-
tion in plasma KC, hyperoxia did not affect LPS-induced cytokine concentrations.
Effects of hyperoxia during experimental human endotoxemia. Demographic characteristics 
and safety. Demographic characteristics of the subjects are listed in Table  1 and were similar among 
the groups. Hyperoxia was well tolerated. No (serious) adverse events occurred during the study.
Oxygenation, hemodynamic parameters, temperature, and symptoms. During the hyperoxic/normoxic 
period, mean PaO2 was similar in the hyperoxia group and hyperoxic endotoxemia group (54.8 ± 3.0 
(411.7 ± 22.8) and 54.1 ± 4.1 (405.9 ± 31.1) kPa (mmHg), p = 0.89), whereas PaO2 in the hyperoxic 
endotoxemia group was higher than in the normoxic endotoxemia group (15.2 ± 0.7 (114.3 ± 5.5) kPa, 
p < 0.0001, Fig. 2a). PaCO2 was 5.0 ± 0.3 (37.8 ± 1.9) kPa in the hyperoxia group, 5.5 ± 0.2 (40.9 ± 1.2) 
kPa in the hyperoxic endotoxemia group, and 5.3 ± 0.2 (39.5 ± 1.7) kPa in the normoxic endotoxemia 
group (Fig. 2b). After an initial increase, PaCO2 decreased over time in the hyperoxia group. A similar 
pattern was observed in the normoxic endotoxemia and hyperoxic endotoxemia groups, with no differ-
ences between these groups (Fig. 2b). Lactate levels were in the normal range (< 2 mmol/L) throughout 
the experiment in all subjects. In all groups, mean arterial pressure (MAP) decreased over time, with no 
difference between the normoxic and hyperoxic endotoxemia groups (Fig. 2c).
In the hyperoxia group, the heart rate gradually increased during the day, while a pronounced increase 
was observed in both endotoxemic groups (Fig. 2d). Endotoxemia resulted in a typical increase in tem-
perature of approximately 1.5 °C (Fig. 2e), and flu-like symptoms (median [IQR] peak symptom scores 
1.5 h after LPS administration of 5.9 [0.81] and 8.7 [1.7] in the normoxic and hyperoxic endotoxemia 
groups, p = 0.20), both of which were not influenced by hyperoxia.
Plasma cytokines. Plasma cytokine concentrations were below the lower detection limit of the assay at 
all time-points in the hyperoxia group. LPS administration resulted in increased plasma concentrations 
of TNFα , IL-6, IL-8, and IL-10 in all subjects. No differences between the normoxic and hyperoxic 
endotoxemia groups were observed (Fig. 3).
Circulating leukocytes. Numbers of circulating neutrophils, monocytes, and lymphocytes changed sig-
nificantly, but to no clinically relevant extent, over time in the hyperoxia group (Fig. 4). LPS administra-
tion typically resulted in neutrophilia, with transient lympho- and monocytopenia. Hyperoxia did not 
affect LPS-induced changes in any of the leukocyte subsets.
Ex vivo cytokine production . In the hyperoxia group, ex vivo production of TNFα was slightly increased 
at several time-points, but no clear relationship with the period of hyperoxia was evident (Fig.  5a). 
Furthermore, IL-6 production was unaffected (Fig. 5b). As circulating monocytes decrease during endo-
toxemia, ex vivo cytokine production could not be assessed one to three hours after LPS administration. 
As expected, in both endotoxemic groups leukocyte cytokine production capacity was blunted four and 
eight hours after LPS-administration due to endotoxin tolerance, which fully recovered the subsequent 
day. There were no differences in ex vivo cytokine production between the normoxic and hyperoxic 
endotoxemia groups.
Neutrophil phagocytosis and ROS generation. Neutrophil phagocytosis was similar in the normoxic and 
hyperoxic endotoxemia groups, with no clear changes over time following LPS administration (Fig. 6a). 
Intracellular ROS generation was not affected in the hyperoxia group at any time-point. Also, no differ-
ences were observed between both endotoxemic groups (Fig. 6b).
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Discussion
In the present study, we demonstrate that short-term hyperoxia neither induces increased levels of 
cytokines in itself, nor modulates the cytokine response during systemic inflammation induced by 
Figure 1. Cytokine concentrations in different compartments in mice. Plasma, spleen, liver, and lung 
concentrations of (a) TNF-α , (b) IL-6, (c) KC, and (d) IL-10 150 minutes after normoxia/hyperoxia 
(90 minutes after LPS/placebo administration). Concentrations are represented as mean ± SEM. *indicates 
p < 0.05.
HYPER NORM-E HYPER-E p
Age [yr) 23 [20–24] 21 [20–23] 21 [20–24] 0.68
Height [cm) 182 [178–184] 185 [180–192] 182 [179–189] 0.60
Weight [kg) 76 [74–84] 75 [69–86] 72 [67–80] 0.61
BMI [kg/m2) 23.8 [22.8-24.8] 22.2 [20.5-24.2] 22.5 [18.8-24.3] 0.28
Table 1.  Demographic characteristics. Data obtained during screening visit and presented as median 
[interquartile range]. NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, HYPER: 
hyperoxia, yr: years; cm: centimeter, kg: kilogram, BMI: body mass index, m: meter.
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endotoxin administration in mice and healthy volunteers. In addition, both in the presence and absence 
of systemic inflammation in humans, no relevant effects of short-term hyperoxia were observed on 
temperature, flu-like symptoms, leukocyte counts, ex vivo whole blood cytokine production, neutrophil 
phagocytosis, and neutrophil ROS generation. To the best of our knowledge, we are the first to investi-
gate the intrinsic immunomodulatory effects of hyperoxia in a standardized and well-controlled model 
of systemic inflammation in humans in vivo.
Our findings appear to be in contrast with previous animal studies reporting anti-inflammatory 
effects of hyperoxia during systemic inflammation. Although exposure to 100% oxygen for 20 hours or 
to 70% oxygen for 48 hours did not affect plasma TNFα levels after CLP in rats, intermittent exposure to 
100% oxygen for 6 hours per day reduced plasma TNFα concentrations12. Similarly, intermittent hyper-
oxia for 2–3 hours attenuated plasma TNFα and IL-6 levels 24 hours after zymosan administration in 
mice10. Paradoxically, the same authors showed that both shorter and longer exposure to 100% oxygen 
nullified the anti-inflammatory effects, without a clear explanation10. The discrepant results between 
these studies and ours might be explained by the use of more prolonged and severe models of inflamma-
tion. Prolonged inflammation may lead to a vicious cycle by causing tissue hypoxia, which subsequently 
results in the release of danger associated molecular patterns (DAMPs), in turn leading to aggravation 
of the inflammatory response17. Along these lines, in animal models of severe sepsis and septic shock, 
hyperoxia was shown to improve tissue oxygenation and organ function, ultimately resulting in better 
survival18,19. Therefore, the previously observed beneficial effects of hyperoxia on systemic inflammation 
might be attributable to the prevention of tissue hypoxia and therefore interruption of the vicious cycle, 
rather than intrinsic immunosuppressive effects. The short-term murine endotoxemia model used in the 
Figure 2. Blood gas parameters, hemodynamics, and temperature in healthy volunteers. (a) arterial 
oxygen pressure (PaO2), (b) arterial carbon dioxide pressure (PaCO2), (c) mean arterial pressure (MAP), 
(d) heart rate, and (e) tympanic temperature. The period of hyperoxia or normoxia is indicated with a grey 
box. In the endotoxemia groups, LPS was administered at T = 0 hours. Data are expressed as mean ± SEM. 
NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
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Figure 3. Plasma cytokine concentrations in healthy volunteers. Plasma concentrations of (a) tumor 
necrosis factor (TNF)α , (b) interleukin (IL)-6, (c) IL-8 and (d) IL-10. The period that subjects were fitted 
with the respiratory helmet and breathed hyperoxic or normoxic air is indicated with a grey box. In the 
endotoxemia groups, LPS was administered at T = 0 hours. Data are expressed as median with interquartile 
range. NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
Figure 4. Circulating leukocytes in healthy volunteers. Numbers of circulating (a) neutrophils,  
(b) monocytes and (c) lymphocytes. The period that subjects were fitted with the respiratory helmet 
and breathed hyperoxic or normoxic air is indicated with a grey box. In the endotoxemia groups, LPS 
was administered at T = 0 hours. Data are expressed as mean ± SEM NORM-E: normoxic endotoxemia, 
HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
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present study is very unlikely to have resulted in tissue hypoxia, and the human endotoxemia model is 
naturally too mild to cause significant hemodynamic instability and tissue hypoxia.
Human in vivo studies on the effects of hyperoxia on the inflammatory response are scarce, and have 
mainly been performed in the perioperative setting. In a trial in patients undergoing elective thyroid 
surgery, a perioperative FiO2 of 80% resulted in decreased levels of postoperative plasma C-reactive 
protein, IL-1β , and IL-6 compared with a FiO2 of 30%. The authors suggest that hyperoxia prevented 
wound hypoxia and consequently attenuated inflammation20. In contrast, hyperoxic ventilation in coro-
nary artery bypass graft surgery resulted in a small, but significant, increase in plasma IL-6 on the first 
postoperative day21. However, this could not be reproduced in an identical study performed by the same 
group, where hyperoxia did not affect postoperative plasma concentrations of IL-6, IL-8, TNFα , IL-1a, 
IL-1β , and IL-1022. A number of randomized clinical trials have been conducted investigating periop-
erative hyperoxia as a means to prevent surgical site infections. Meta-analyses of these studies report a 
slight beneficial effect in e.g. colorectal surgery6,23.
Although in vitro, hyperoxia has been shown to enhance LPS-induced whole blood cytokine produc-
tion7, we now demonstrate that hyperoxia in vivo does not affect ex vivo whole blood cytokine responses. 
Figure 5. Ex vivo whole blood stimulation in healthy volunteers. (a) Tumor necrosis factor (TNF)α and 
(b) interleukin (IL)-6 cytokine production in whole blood stimulated ex vivo with LPS. Data are expressed 
as median with interquartile range. NORM-E: normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, 
HYPER: hyperoxia.
Figure 6. Neutrophil phagocytosis and ROS generation in healthy volunteers. (a) Neutrophil phagocytic 
index and (b) neutrophil intracellular ROS generation. Data are expressed as mean ± SEM. NORM-E: 
normoxic endotoxemia, HYPER-E: hyperoxic endotoxemia, HYPER: hyperoxia.
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As such, the present findings suggest that hyperoxia in vivo does not result in (lasting) leukocyte repro-
gramming that modifies cytokine production capacity. Previous studies have also described that hyper-
oxia inhibits phagocytosis of alveolar macrophages in vitro9 and in vivo in mice24, whereas neutrophil 
phagocytosis and ROS generation was shown to be enhanced in vitro25. In contrast, ex vivo neutrophil 
ROS generation and phagocytosis remained unaffected after exposure of healthy volunteers to hyperbaric 
hyperoxia26, which is in agreement with our findings. Taken together, these results suggest that the effects 
of hyperoxia on phagocytosis and killing is highly cell-type specific.
The absence of immunomodulatory effects of hyperoxia in the present study tempers expectations of 
utilizing therapeutic hyperoxia in acute inflammation. In addition, the concept of therapeutic hyperoxia 
requires cautious consideration for several other reasons.
First, an important drawback is the risk of oxygen toxicity27. The lungs, being the gas exchange inter-
face, are at the greatest risk of hyperoxia-induced injury15. Pulmonary oxygen toxicity ultimately resem-
bles the clinical and pathological characteristics of ARDS27, as demonstrated in mice exposed to 100% 
oxygen for up to 48 hours16. These mice developed neutrophil infiltration and increased IL-6 and TNFα 
levels in the bronchial alveolar lavage fluid within 12 hours, followed by alveolar congestion, wall thick-
ening, and hemorrhage16. Other animal studies have shown that especially in acute lung injury, high 
FiO2 levels are detrimental as well28. The current study was not primarily designed to assess oxygen 
toxicity, as this has only been described after long-term hyperoxia24,28,29. Nevertheless, we demonstrate 
that short-term hyperoxia neither causes pulmonary inflammation in itself, nor does it aggravate the 
pulmonary inflammatory response induced by systemic LPS administration in mice.
A second concern is related to possible hemodynamic effects of hyperoxia, as it was shown to induce 
vasoconstriction and hence reduced tissue blood flow30,31 as well as reduced coronary blood flow and 
myocardial oxygen consumption32 in humans. Although we did not observe an effect of hyperoxia on 
gross hemodynamic parameters during human endotoxemia, we did not assess regional blood flow, oxy-
gen consumption, or vascular resistance. Currently, the net effects of hyperoxia on hemodynamic param-
eters and oxygen delivery in patients with sepsis are unknown.
Finally, hyperoxia at ICU admission was shown to be associated with increased mortality in a 
meta-analysis of observational cohort studies5, which might be related to the issues raised in the previ-
ous points. Of note, this overall effect might be attributed to a large subgroup of cardiac arrest patients 
in the meta-analysis, in whom hyperoxia has obvious detrimental effects. Naturally, physicians may be 
tempted to treat the most severely ill patients with a higher FiO2, therefore, hyperoxia could represent a 
confounding factor instead of a direct cause of increased mortality in these observational studies.
This study has several strengths. First, results obtained in animals were confirmed in a human in vivo 
model of systemic inflammation. This is important, as the acute inflammatory response in human and 
animal models may differ considerably33. Second, it is unlikely that tissue oxygenation was compromised 
in our experiments. Therefore, conclusions can be drawn about the intrinsic effect of hyperoxia on the 
inflammatory response, without interference of tissue hypoxia effects or (other) alterations that might 
emerge during long periods of hyperoxia. Nevertheless, endotoxemia models do not reflect all aspects 
of the complex systemic inflammatory response encountered in many critically ill patients. Therefore, 
the effects of oxygenation on outcome in systemically inflamed ICU patients remain to be determined. 
Data from a recently preliminary terminated clinical trial in which sepsis patients were randomized to 
either hyperoxia or normoxia and hypertonic or isotonic saline in a 2 × 2 factorial design (HYPER2S, 
ClinicalTrials.gov identifier NCT01722422), and an ongoing study on liberal versus restrictive oxygen-
ation in ICU patients with systemic inflammation (O2-ICU ClinicalTrials.gov identifier NCT02321072) 
will hopefully answer this important question.
In conclusion, short-term hyperoxia does not affect the inflammatory response induced by admin-
istration of endotoxin in mice and man. These results indicate that hyperoxia does not exert direct 
anti-inflammatory effects, and suggest that the previously reported beneficial effects in animal models 
of more prolonged and severe inflammation are due to preserved tissue oxygenation. Our data tempers 
expectations of using hyperoxia as an immunomodulatory treatment strategy in patients. Intervention 
studies in patients are ongoing and are expected to provide evidence for tailoring oxygenation in criti-
cally ill patients.
Materials and Methods
Effects of hyperoxia during murine endotoxemia. Animals. All procedures were in accordance 
with the requirements of the Dutch Experiments on Animals Act, the EC Directive 86/609 and approved 
by the Animal Ethics Committee of the Radboud University Medical Centre. A total of 32 male Balb/c 
mice (Charles River Laboratories International, Inc., L’Arbresle Cedex, France), aged six to eight weeks 
were used.
Reagents. Lipopolysaccharide (LPS, E. Coli, serotype 0111:B4) was obtained from Sigma–Aldrich 
(St Louis, MO, USA), dissolved in sterile 0.9% NaCl, and administered intraperitoneally at a dose of 
5 mg/kg. Sterile 0.9% NaCl was used as placebo.
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Experimental protocol. Mice were randomized into four groups (n = 8 per group); 1. normoxia-placebo. 
2. normoxia-LPS. 3. hyperoxia-placebo. 4. hyperoxia-LPS. One hour before LPS/ placebo administration, 
mice were placed in an airtight cage with a continuous airflow of room air (21% oxygen, normoxia) or 
100% oxygen (hyperoxia) to ensure a hyperoxic state during the initiation of inflammation. Ninety min-
utes after LPS/ placebo administration, when plasma levels of the archetypal pro-inflammatory cytokine 
TNFα (primary endpoint) reach their maximum34,35, mice were sacrificed by exsanguination through 
orbita extraction under deep isoflurane anesthesia. Blood was collected in ethylenediaminetetraacetic 
acid (EDTA)-containing tubes (MiniCollect, Greiner bio-one, Alphen a/d Rijn, the Netherlands), centri-
fuged (14000 g, 5 minutes, room temperature), and plasma was stored at − 80°C until batch-wise analysis. 
Liver, spleen, and lungs were snap-frozen and stored at − 80 °C until further analysis.
Cytokine analysis. Liver, spleen, and lung tissue was homogenized for 5 minutes at 50 Hz in Tissue 
Protein Extraction Reagent (Life Technologies, Bleiswijk, the Netherlands) containing protease inhibitors 
(complete EDTA-free tablets, Roche, Woerden, The Netherlands) using a Tissuelyzer LT instrument and 
5 mm stainless steel beads (both from Qiagen, Venlo, the Netherlands Plasma and tissue homogenate 
concentrations of Tumor Necrosis Factor (TNF)-α , interleukin (IL)-6,keratinocyte-derived chemokine 
(KC, murine homologue of IL-8), and IL-10 were measured batch-wise using a Luminex assay (detec-
tion range 32–1000000 pg/mL) according to the manufacturer’s instructions (Milliplex, Merck Millipore, 
Billerica, MA, USA). Tissue cytokine concentrations were normalized to total protein content deter-
mined by bicinchoninic acid assay (BCA Protein Assay, Life Technologies, Bleiswijk, the Netherlands).
Effects of hyperoxia during experimental human endotoxemia. Subjects and study design. Data 
was obtained from two larger trials on immunologic effects of oxygenation (ClinicalTrials.gov identifier 
NCT01889823 and NCT01978158). Experiments were in accordance with the declaration of Helsinki. 
After approval from the local ethics committee of the Radboud University Medical Center, 30 healthy 
male volunteers gave written informed consent to participate in the study. Subjects were screened before 
participation and had a normal physical examination, electrocardiography, and routine laboratory val-
ues. Subjects with febrile illness two weeks before the experiment, use of prescription drugs, or history 
of vagal collapse were excluded. The study was conducted in two phases. The first phase was designed 
to assess safety, feasibility, and immunologic effects of hyperoxia in the absence of systemic inflamma-
tion. In these experiments, 10 subjects were exposed to hyperoxia (fraction of inspired oxygen [FiO2] of 
100%) using an air-tight respiratory helmet (CaStar, StarMed, Italy) for 3.5 hours. In the second phase, 20 
subjects participated in endotoxemia experiments: they were randomized to either hyperoxia (as above, 
hyperoxic endotoxemia group, n = 10), or normoxia (FiO2 of 21% using the same respiratory helmet, 
normoxic endotoxemia group, n = 10). The period of hyperoxic exposure was chosen to assure a hyper-
oxic state at the initiation of the inflammatory response and throughout its acute phase, during which 
most inflammatory cytokines reach their maximum levels36,37. Apart from LPS administration, study 
protocols of the two phases were identical.
Study procedures. Experiments were conducted at the research unit of the intensive care department. 
Subjects refrained from caffeine and alcohol 24 hours before the experiment, and refrained from any 
intake of food and drinks 10 hours before the experiment. A venous and arterial cannula were placed 
for hydration, arterial blood pressure monitoring, and blood withdrawal. Heart rate was recorded 
with a three-lead electrocardiogram and peripheral saturation was measured using pulse oximetry. 
Hemodynamic data were recorded from a Philips MP50 patient monitor every 30 seconds using an 
in-house developed system. Every 30 minutes, temperature was measured using a tympanic thermometer 
(FirstTemp Genius 2; Covidien, Dublin, Ireland), and flu-like symptoms (headache, nausea, shivering, 
muscle and back pain) were scored on a six-point scale (0 = no symptoms, 5 = worst ever experienced), 
resulting in a total symptom score of 0–25.
After baseline measurements (t = − 1 h), subjects were fitted with the respiratory helmet and normoxia 
or hyperoxia was initiated. The inflowing gas composition and the gas composition within the helmet were 
continuously monitored (%O2 and %CO2) using gas analyzers (Philips Airway Gases analyser M1026A, 
Philips Medical Systems, Boebligen, Germany) connected to patient monitors (Hewlett Packard Model 
M1166A 68S, Geneva, Switzerland and Capnomac Ultima, DATEX-OHMED, Helsinki, Finland). To pre-
vent carbon dioxide build up, airflow was titrated to assure an inspiratory CO2 < 1%. One hour after ini-
tiation of normoxia or hyperoxia (t = 0 h), purified LPS (US Standard Reference Endotoxin Escherichia 
Coli O:113) obtained from the Pharmaceutical Development Section of the National Institutes of Health 
(Bethesda, MD, USA) was administered intravenously at a dose of 2 ng/kg in both endotoxemia groups. 
After 3.5 hours of normoxia or hyperoxia (t = 2.5 h), the helmet was removed and all subjects breathed 
room air for the rest of the experiment.
Blood gas parameters, lactate, and leukocyte counts. Blood gas parameters and lactate were analyzed 
in lithium heparin (LH)-anticoagulated arterial blood immediately after withdrawal using CG4+ car-
tridges and an i-STAT blood gas analyzer (Abbott, Libertyville, IL, USA). Analysis of leukocyte counts 
and differentiation was performed in EDTA-anticoagulated blood using routine patient sample analysis 
methods (flow cytometric analysis on a Sysmex XE-5000,The Netherlands).
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Plasma cytokine concentrations and ex vivo whole blood stimulation. EDTA-anticoagulated blood was 
centrifuged immediately after withdrawal (2000 g, 10 minutes, 4 °C) and plasma was stored at − 80 °C 
until analysis. “Concentrations of TNFα , IL-6, IL-8, and IL-10 were analyzed batch-wise using a Luminex 
assay (detection range 3.2-10000 pg/mL) according to the manufacturer’s instructions (Milliplex, 
Millipore, Billerica, MA, USA).” Leukocyte cytokine production capacity was assessed by ex vivo whole 
blood LPS stimulation using an in-house developed system38. Briefly, 0.5 mL LH-anticoagulated blood 
was added to pre-filled tubes with 2 mL culture medium or 2 mL culture medium supplemented with 
12.5 ng/mL LPS (final LPS concentration: 10 ng/mL). After 24 hours of incubation at 37 °C, samples were 
centrifuged, and supernatants were stored at − 80 °C until batch-wise analysis. Concentrations of TNFα 
and IL-6 were determined using ELISA according to the manufacturer’s instructions (Duoset, R&D sys-
tems, Minneapolis, MN, USA). Cytokine concentrations were normalized to monocyte counts (the main 
cytokine-producing cells in whole blood stimulation assays39).
Neutrophil phagocytosis assay. Neutrophil phagocytosis was measured using the pHrodo Red E. coli 
BioParticles Phagocytosis Kit for Flow Cytometry according to the manufacturer’s instructions (Life 
Technologies, Bleiswijk, the Netherlands). Briefly, 100 μ L LH-anticoagulated blood was incubated with 
pHrodo Red E. coli BioParticles for 15 minutes (at 37 °C or on ice). Thereafter, erythrocytes were lysed, 
the leukocyte pellet was washed and stored in 1% paraformaldehyde solution. Analysis was performed 
using a Cytomics FC500 flow cytometer and Kaluza Analysis Software (both from Beckman Coulter; 
Galway, Ireland). Neutrophils were gated based on forward and side scatter characteristics. Using the 
samples incubated on ice as negative control, the percentage pHrodo-positive neutrophils in the phyco-
erythrin channel was determined. Phagocytic index was calculated as the percentage of pHrodo-positive 
neutrophils multiplied by the Mean fluorescence intensity (MFI) of the pHrodo-positive neutrophil 
population.
Neutrophil intracellular ROS generation. Neutrophil ROS generation was quantified using 
2′ ,7′ -dichlorofluorescein diacetate (DCFH-DA; Sigma, St Louis, MO, USA), as described previously40. 
Briefly, LH-anticoagulated blood was incubated with 0.06 mM DCFH-DA (30 minutes, 3 °C, 400 rpm), 
the reaction was stopped with 3 mM EDTA, and samples were centrifuged (430 g, 5 minutes, 4 °C). 
Erythrocytes were lysed (BD Pharm Lyse, Beckton Dickinson, Breda, the Netherlands) and cells were 
washed, after which the leukocyte pellet was resuspended in 3 mM EDTA solution and stored overnight 
at 4°, as pilot work showed that fluorescence remains stable overnight using this method. Analysis was 
performed the following day using a Cytomics FC500 flow cytometer and Kaluza Analysis Software 
(both from Beckman Coulter; Galway, Ireland). Pilot studies have shown that the fluorescence remains 
stable when stored overNeutrophils were gated based on forward and side scatter characteristics, and 
ROS generation was quantified by determining the mean fluorescence of the neutrophil population. ROS 
generation was normalized to baseline levels (t = − 1 h).
Calculations and statistical analysis. Data are expressed as median [interquartile range] or mean ± SEM 
based on their distribution (calculated by Shapiro-Wilk tests). Except for demographic characteristics, all 
non-parametric data were log-transformed before statistical analysis. Differences between groups in the 
murine experiments and between-group differences in mean PaO2, peak levels of flu-like symptoms, and 
demographic characteristics in humans were evaluated using unpaired Student’s t-tests or Kruskall-Wallis 
tests. Within-group differences over time in the hyperoxia group were analyzed using one-way analysis of 
variance (ANOVA). Two-way ANOVA (interaction term) was used to assess differences between endo-
toxemic groups over time. A p-value of < 0.05 was considered statistically significant. Statistical calcu-
lations were performed using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA).
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